Sarepta Therapeutics (SRPT) Tops Q3 EPS by 54c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($0.80), $0.54 better than the analyst estimate of ($1.34). Revenue for the quarter came in at $230.27 million versus the consensus estimate of $233.93 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• General Mills (GIS) Tops Q1 EPS by 3c
• General Mills posts lower Q1 sales, reaffirms fiscal 2027 targets